

1 ***Pseudomonas aeruginosa* utilises host-derived polyamines to facilitate**
2 **antimicrobial tolerance**

3

4

5 Chowdhury M. Hasan¹, Angharad E. Green¹, Adrienne A. Cox^{1,2}, Jack White,² Trevor Jones¹,
6 Craig Winstanley¹, Aras Kadioglu¹, Megan Wright², Daniel R. Neill^{1,*}, and Joanne L.
7 Fothergill^{1,*}

8

9 ¹ Department of Clinical Infection, Microbiology and Immunology, Institute of Infection,
10 Veterinary and Ecological Sciences, University of Liverpool, United Kingdom

11 ² School of Chemistry and Astbury Centre for Structural Molecular Biology, University of
12 Leeds, United Kingdom

13

14

15 **Correspondence:** Joanne L Fothergill (j.fothergill@liverpool.ac.uk, +44(0)151 79 59646) or
16 Daniel R Neill (d.neill@liverpool.ac.uk, +44(0)151 79 59622), Department of Clinical
17 Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological
18 Sciences, Ronald Ross Building, 8 West Derby Street, Liverpool, UK, L69 7BE

19

20 * Equal contributions

21

22 The authors have declared that no conflict of interest exists.

23

24

25

26

27

28

29 **Abstract**

30 *Pseudomonas aeruginosa* undergoes diversification during infection of the cystic fibrosis (CF)
31 lung. Understanding these changes requires model systems that capture the complexity of
32 the CF lung environment. We previously identified loss-of-function mutations in the two-
33 component regulatory system sensor kinase gene *pmrB*, in *P. aeruginosa* from CF and from
34 experimental infection of mice. Here, we demonstrate that whilst such mutations lower *in*
35 *vitro* MICs for multiple antimicrobial classes, this is not reflected in increased antibiotic
36 susceptibility *in vivo*. Loss of PmrB impairs aminoarabinose modification of
37 lipopolysaccharide, increasing the negative charge of the outer membrane and promoting
38 uptake of cationic antimicrobials. However, *in vivo*, this can be offset by increased membrane
39 binding of other positively charged molecules present in lungs. The polyamine spermidine
40 readily coats the surface of PmrB-deficient *P. aeruginosa*, reducing susceptibility to
41 antibiotics that rely on charge differences to bind the outer membrane and increasing biofilm
42 formation. Spermidine is elevated in lungs during *P. aeruginosa* infection in mice and during
43 episodes of antimicrobial treatment in people with CF. These findings highlight the need to
44 study antimicrobial resistance under clinically relevant environmental conditions. Microbial
45 mutations carrying fitness costs *in vitro* may be advantageous during infection, where host
46 resources can be utilised.

47 Introduction

48 *Pseudomonas aeruginosa* is a ubiquitous environmental bacterium and a metabolically
49 versatile opportunistic pathogen, responsible for severe, acute nosocomial infections (1, 2).
50 It is also the most frequently recovered pathogen of the cystic fibrosis (CF) lung (3), where it
51 causes chronic infection that is associated with pulmonary exacerbations and declining lung
52 function. Such infections are difficult to treat, due in part to intrinsic antimicrobial resistance
53 of *P. aeruginosa*, together with adaptive resistance mechanisms induced by the presence of
54 antimicrobial agents or other environmental factors (4). The chronic nature of *P. aeruginosa*
55 infection of the CF lung necessitates long-term, high dose antimicrobial therapy, creating
56 conditions conducive to the emergence and selection of acquired resistance mechanisms
57 (5). Phenotypic flexibility and a large genome encoding complex regulatory machinery makes
58 chronically colonised *P. aeruginosa* a challenge to eradicate and necessitates frequent
59 review of treatment regimens for people with CF.

60

61 Lipopolysaccharide (LPS) is a key component of the Gram-negative outer membrane and
62 can be stabilized by the addition of divalent cations, including Mg^{2+} and Ca^{2+} . Cationic
63 antimicrobials, including polymyxin B, colistin and host-derived peptides such as LL37, exert
64 their effects via disruption of cell membrane integrity, but rely on charge differentials with the
65 outer membrane in order to bind (6). Modifications of LPS that reduce cationic antimicrobial
66 binding affinity and penetration can result in resistance (7). One such modification is the
67 addition of positively charged 4-amino-4-deoxy-L-arabinose (L-Ara4N) to the lipid A
68 component of LPS (8), mediated in *P. aeruginosa* by the proteins encoded by the
69 *arnBCADTEF-ugd* operon (9). Expression of operon genes is regulated by two component
70 signalling systems, such as PhoPQ and PmrAB (10, 11), which are activated under conditions
71 of locally decreased divalent cation concentrations. This ensures that the charge of the
72 membrane can be maintained when Mg^{2+} and Ca^{2+} are limited. PhoPQ- and PmrAB-induced

73 expression of the *arn* operon results in high level resistance to both cationic peptides and
74 aminoglycosides (12). Specific mutations in *pmrAB* have been implicated in polymyxin
75 resistance, via upregulation of both the lipid A deacylase *pagL* and the *arn* operon (13-15).

76

77 Expression of genes *PA4775*, *speE2* (*PA4774*) and *speD2* (*PA4773*) (16), located adjacent
78 to *pmrAB* on the chromosome, is also induced by Mg²⁺ limiting conditions, due to the
79 presence of a PmrA binding site close to *speD2* (6). These genes are involved in the
80 synthesis of the polyamine spermidine. During environmental stress or periods of low cation
81 availability, PmrAB stimulates polyamine synthesis and these coat the bacterial surface,
82 increasing the outer membrane charge and providing protection against both antimicrobial
83 agents and oxidative stress (6).

84

85 Polyamines are polycationic hydrocarbons, containing two or more amine groups, and are
86 abundant across all three kingdoms of life. Putrescine, spermidine and cadaverine, the
87 principal polyamines of prokaryotes, have been implicated in growth, iron and free radical
88 scavenging, acid resistance, biofilm formation, protection from the phagolysosome,
89 interaction with components of cell envelopes and antimicrobial resistance (17). However,
90 there is uncertainty regarding the effect, if any, that polyamines have on antimicrobial
91 susceptibility in *P. aeruginosa*. Increased susceptibility to multiple classes of antibiotics was
92 observed when PAO1 was cultured with polyamines, (18) but addition of exogenous
93 polyamines to a PAO1 lacking a functional spermidine synthase (*speE2*) partially protected
94 the outer membrane from polymyxin B (6). Whilst the extent of the role played by polyamines
95 in *P. aeruginosa* growth, virulence and antimicrobial resistance has not been fully determined,
96 it is notable that spermine was found to be elevated in the airways of those with CF and that
97 levels have been reported to decrease during treatment of pulmonary exacerbations (19),
98 whilst those of putrescine have been found to decrease(20).

99

100 In a previous study, we identified loss of function mutations in *pmrB* in *P. aeruginosa* isolated
101 from the airways of mice, following experimental infection, and in isolates taken from people
102 with CF (21, 22). These isolates showed enhanced susceptibility to multiple classes of
103 antibiotics. Here, we sought to understand why loss of function *pmrB* mutations might be
104 retained in *P. aeruginosa*, in an environment of prolonged antimicrobial exposure, such as
105 the CF lung. As we had observed altered LPS structure in *pmrB* mutants (22), we
106 hypothesised that host-derived molecules might play a role in stabilising the outer membrane
107 of *P. aeruginosa* *in vivo*, thereby overcoming the lack of PmrAB-driven modifications of lipid
108 A. Here, we propose that the host cationic polyamine spermidine acts in this way, negating
109 the antimicrobial susceptibility phenotype of *P. aeruginosa* lacking functional PmrB. These
110 findings highlight the need to conduct antimicrobial susceptibility testing under
111 environmentally-relevant conditions.


112

113 **Results**

114 ***P. aeruginosa* lacking PmrB show enhanced antimicrobial susceptibility *in vitro* but 115 not *in vivo***

116 We previously described susceptibility to multiple classes of antibiotics in *P. aeruginosa* with
117 naturally acquired loss of function mutations in *pmrB* and in a *pmrB*-deletion strain of LESB65
118 (22). To determine whether this susceptibility would result in improved infection outcomes
119 following onset of antimicrobial therapy, we infected mice with LESB65 or a LESB65 mutant
120 lacking *pmrB* (LESB65 Δ *pmrB*) and then treated with intra-nasal colistin at 6 and 24 h post-
121 infection. In LESB65-infected mice, colistin treatment led to significant reductions in the
122 number of *P. aeruginosa* recovered from both the upper airways (nasopharynx and sinuses)
123 (Figure 1A) and the lungs (Figure 1B), with four out of eight mice clearing the infection
124 completely. By contrast, colistin treatment did not significantly alter the bacterial burdens
125 recovered from LESB65 Δ *pmrB*-infected animals (Figure 1A and B). Consistent with our

126 previous findings, the LESB65 $\Delta pmrB$ strain colonised lungs at a higher density than its wild
127 type parent strain (Figure 1B). We subsequently performed *in vitro* antimicrobial susceptibility
128 testing with bacteria recovered from the infections and confirmed that LESB65 $\Delta pmrB$
129 retained its susceptibility to colistin *in vitro* (Supplementary Figure 1).



130


131 **Figure 1. Difference in *in vitro* and *in vivo* antimicrobial susceptibility in PmrB-deficient *P. aeruginosa*.**
132 LESB65 or LESB65 $\Delta pmrB$ colony forming units (CFU) in (A) sinuses and (B) lungs at 48 hours post-infection.
133 Mice were intranasally infected with 2×10^6 CFU *P. aeruginosa*, at 6 and 24 hours post-infection, mice were
134 intranasally administered a 50 μ l dose of 20 μ g colistin or PBS control. Each circle represents an individual
135 mouse and p values were determined by two-way ANOVA with Bonferroni correction. Data are representative
136 of two independent experiments.

137

138 **Proteomics analysis suggests a switch from polyamine synthesis to uptake and
139 utilisation in LESB65 $\Delta pmrB$**

140 To further explore the environment-dependent antimicrobial susceptibility profile of LESB65
141 and LESB65 $\Delta pmrB$, we revisited proteomics data obtained from late-exponential bacterial
142 cultures grown in LB (22). We identified inter-strain abundance differences in a group of
143 functionally related proteins involved in polyamine transport, biosynthesis and metabolism.
144 Bacteria can synthesise polyamines or acquire them via environmental uptake. Genes
145 involved in polyamine synthesis are co-transcribed with *pmrA* and *pmrB* (23) and the proteins
146 encoded by those genes (SpeD2, SpeE2 and PA4775) were found at greatly reduced

147 abundance both in LESB65 $\Delta pmrB$ and in an LESB65-derived isolate with a naturally-
148 acquired missense mutation in *pmrB* (LESB65*pmrB*^{L255Q}) (Figure 2A). There is a *pmrA*
149 binding sequence close to the start codon of *speD2* (6) and these data suggest that in the
150 absence of a functional PmrAB system, expression of the operon is significantly reduced.
151 However, the reduced abundance of polyamine synthesis proteins in these strains appears
152 to be offset by a corresponding increased abundance of the polyamine binding, uptake and
153 utilisation proteins of the SpuABCDEFGHI operon (Figure 2B). Of the six proteins of this
154 operon that were detected in proteomics analysis, four were significantly more abundant in
155 both LESB65 $\Delta pmrB$ and LESB65*pmrB*^{L255Q}, as compared to LESB65.




165

166 **Spermidine is abundant in both the airways and increases during infection and**
167 **antimicrobial treatment**

168 The apparent increase in polyamine binding and acquisition proteins in the *pmrB* mutant
169 strains may be advantageous in environments that are rich in free polyamines. Others have
170 reported polyamine abundance in CF sputum and changes in bioavailability associated with
171 pulmonary exacerbations(19, 20). As the spermidine synthesis proteins were significantly
172 decreased in abundance in PmrB-deficient *P. aeruginosa*, we sought to determine whether
173 the polyamine could instead be scavenged from the environment. We measured spermidine
174 levels in the sinuses and lungs of both uninfected mice and those with chronic *P. aeruginosa*
175 LESB65 infection (Figure 3). Spermidine was detectable at comparable concentrations in
176 sinuses and lungs and was found to increase in the context of infection. This increase is
177 unlikely to result from polyamine production in *P. aeruginosa*, as the levels of spermidine
178 produced by high density cultures of LESB65 or LESB65 $\Delta pmrB$ were ~1000-fold lower than
179 those detected in respiratory tissues (Supplementary Figure 2).

180


181 We also detected free polyamines in CF sputum (Figure 4). Spermidine was quantifiable in
182 samples from 18 of 19 people tested (Figure 4A). There was considerable inter- (Figure 4A)
183 and intra- (Figure 4B) participant variability in sputum spermidine levels, but levels were
184 higher during periods of antimicrobial treatment (Figure 4C), suggesting potential for
185 polyamines to influence treatment efficacy.



186

187 **Figure 3. Spermidine is abundant in the murine respiratory tract and bioavailability increases during *P.***
188 ***aeruginosa* infection.** Concentration of spermidine in the sinuses and lungs of mice at 48 hours post intranasal
189 administration of PBS (-) or LESB65 (+). Spermidine was measured by ELISA and each square represents a
190 tissue sample from an individual mouse. Significance was determined by two-way ANOVA with Bonferroni
191 correction. Data are from a single experiment.

192




193

194 **Figure 4. Spermidine is detectable in CF sputum.** Concentration of spermidine in CF sputum, determined by
195 competition ELISA. **(A)** Spermidine levels in 19 study participants. Between 1 and 13 samples were available
196 per participant. No two samples from the same participant were collected at the same visit. **(B)** Changes in
197 spermidine abundance in sputum from a single participant over time. **(C)** Collected samples were defined as
198 baseline, treatment or pulmonary exacerbation, defined by participant clinical data. Whiskers show 10-90
199 percentile. Significance was determined by one-way ANOVA with Dunnett's multiple comparison testing. Data
200 are from a single experiment.

201

202 **PmrB genotype influences *P. aeruginosa* surface interactions with spermidine**

203 Having demonstrated that spermidine is available within the airways, we next sought to
204 characterise whether *P. aeruginosa* might interact with this cationic molecule. Using purified
205 spermidine tagged with fluorescent nitrobenzoxadiazole (NBD), we first investigated whether
206 the polyamine could interact with the bacterial surface and if such interactions were transient
207 or prolonged. For these assays, we used non-toxic concentrations of spermidine, determined
208 by broth microdilution (Supplementary Figure 3). LESB65 and LESB65 $\Delta pmrB$ were co-
209 incubated with 4 mM unlabelled spermidine or spermidine-NBD for 30 minutes before the
210 bacteria were pelleted by centrifugation and resuspended in PBS. We then determined the
211 extent of spermidine binding to the bacterial surface by flow cytometry. Spermidine-NBD
212 bound both LESB65 and LESB65 $\Delta pmrB$, as evidenced by increasing median fluorescence
213 intensity [MFI] for *P. aeruginosa* co-cultured with labelled vs unlabelled spermidine (MFI 10.4
214 vs 3.00 for LESB65 with spermidine-NBD vs unlabelled spermidine, MFI 73.3 vs 3.13 for
215 LESB65 $\Delta pmrB$, $p<0.0001$ for both strains) (Figure 5). The NBD fluorescence of the
216 LESB65 $\Delta pmrB$ population was significantly higher than that of LESB65 (MFI 73.3
217 LESB65 $\Delta pmrB$ vs 10.4 LESB65, $p<0.001$). Furthermore, fluorescence was retained longer
218 in LESB65 $\Delta pmrB$ cultures (MFI 73.3 at 0 mins, 67.5 at 30 mins, 62.3 at 60 mins, 56.9 at 120
219 mins, 54.6 at 240 mins) than in LESB65 cultures (MFI 10.4 at 0 mins, 7.30 at 30 mins, 5.49
220 at 60 mins, 4.60 at 120 mins, 4.59 at 240 mins) (Figure 5), suggesting prolonged binding or
221 uptake in the LESB65 $\Delta pmrB$ strain. Binding, and surface coating of NBD-spermidine to the
222 *P. aeruginosa* membrane was confirmed by fluorescence microscopy (Supplementary Figure
223 4).



224

225 **Figure 5. Prolonged interaction with environmental spermidine in PmrB-deficient *P. aeruginosa*.** LESB65
226 and LESB65 Δ pmrB from mid-log cultures were incubated for 30 minutes with unlabelled spermidine (blue
227 histogram) or spermidine-NBD (all other histograms), then pelleted, washed in saline and resuspended in
228 polyamine-free PBS. Spermidine-NBD binding to *P. aeruginosa* was determined by flow cytometry at 0, 30, 60,
229 120, 180 and 240 minutes after co-incubation. Data are representative of two independent experiments.

230

231 **Surface-coated spermidine protects *P. aeruginosa* from antimicrobials and offsets the
232 susceptibility associated with loss of PmrB function**

233 Polyamines have been implicated in resistance to several classes of antibiotics, with binding
234 of these positively charged molecules to the *P. aeruginosa* membrane reducing charge
235 interactions with cationic antimicrobials (6, 23). The decreased abundance of SpeD2, SpeE2
236 and PA4775 in loss-of-function *pmrB* mutants may, therefore, contribute to the observed
237 increases in antimicrobial susceptibility, under conditions where polyamines cannot be readily
238 scavenged from the environment. However, where polyamines are abundant, the increased
239 polyamine-binding potential of LESB65 Δ pmrB might offset the inherent susceptibility to
240 antimicrobials associated with loss of PmrB function. To explore this idea, we performed MIC
241 assays with *P. aeruginosa* without spermidine, in the presence of spermidine, or with *P.*
242 *aeruginosa* that had been pre-incubated with spermidine and then pelleted and washed

243 before addition of antibiotics. (Table 1). Assays were performed with PmrB-deficient strains
244 on both the LESB65 and PAO1 backgrounds. In both cases, spermidine increased the colistin
245 MIC50 of the *pmrB*-deficient strain, but not the wild type ancestor, by 4-8 fold. This was the
246 case both when the spermidine was present throughout the assay and when strains were
247 pre-incubated with the polyamine. In polyamine-rich environments, such as the respiratory
248 tract, surface-coating of *P. aeruginosa* with cationic polyamines may achieve a comparable
249 outcome to PmrAB-driven L-Ara-4N addition to LPS lipid A, by increasing the positive charge
250 of the outer membrane. This finding may explain why loss-of-function *pmrB* mutations are
251 retained in *P. aeruginosa* causing chronic infection of the CF lung, despite prolonged, high
252 dose antimicrobial treatment.

253

254 **Table 1. Presence of spermidine reduces antimicrobial susceptibility of PmrB-deficient but not wild type**
255 ***P. aeruginosa*.** The concentration of colistin required to inhibit 50 percent of growth (minimum inhibitory
256 concentration [MIC]50) was determined for LESB65, PAO1 and their PmrB-deficient derivatives. Assays were
257 conducted without spermidine, in the presence of 4 mM spermidine, or with bacteria that had been pre-incubated
258 for 30 minutes with 4 mM spermidine and then washed in PBS before addition of antibiotics. Data shown are
259 the median and range of MIC50 values from 5 independent experiments.

Strain	Spermidine throughout	Preincubation with spermidine	MIC50 μ g/ml [Median (range)]
LESB65	-	-	2 (2-4)
	+	-	2 (2-4)
	-	+	2 (1-4)
LESB65 $\Delta pmrB$	-	-	0.25 (0.125-0.5)
	+	-	2 (0.5-4)
	-	+	1 (1)
PAO1	-	-	0.5 (0.5)
	+	-	1 (0.5-1)
	-	+	0.5 (0.25-0.5)
PAO1 $\Delta pmrB$	-	-	0.125 (0.125-0.25)
	+	-	2 (0.5-2)
	-	+	1 (0.5-2)


260

261

262

263 **Exogenous spermidine influences *P. aeruginosa* biofilm formation**

264 Polyamines contribute to biofilm formation in both Gram positive and Gram negative bacterial
265 species (24). They serve as structural components of the extracellular matrix, but also
266 stimulate signalling that can promote or inhibit biofilm formation (25, 26). However, the role
267 of polyamines in *P. aeruginosa* biofilm formation is not well described. To determine whether
268 spermidine-induced reductions in antimicrobial susceptibility in LESB65 $\Delta pmrB$ might be
269 augmented by enhanced biofilm formation, we quantified surface attached biofilm by crystal
270 violet staining. The addition of spermidine to cultures had no effect on LESB65 biofilm but led
271 to a ~2.5-fold increase in LESB65 $\Delta pmrB$ biofilm biomass over a 48 hour period (Figure 6).



272

273

274 **Figure 6. Spermidine promotes biofilm production in PmrB-deficient *P. aeruginosa*.** Surface-attached
275 biofilm production was quantified by crystal violet staining, following 48 hours of culture. Data are expressed as
276 fold-changes in biofilm production vs the no spermidine control for each strain. Data are pooled from three
277 independent experiments.

278

279 **Discussion**

280 Despite their ubiquity and essentiality across all kingdoms of life, understanding of polyamine
281 biology is limited. *P. aeruginosa* can synthesise polyamines from methionine, arginine or
282 ornithine, but also scavenge them from their environment. The expression of *P. aeruginosa*
283 polyamine synthesis, uptake and utilisation genes is under environmental control, including
284 by the PmrAB two-component regulatory system.

285

286 The PmrAB system plays a key role in environmental sensing, stimulating production of
287 polyamines and modification of LPS to buffer the outer membrane charge in conditions of low
288 divalent cation availability (14). Mutations in *pmrB* are frequently identified in *P. aeruginosa*
289 infecting the CF lung (27), and both activating and loss-of-function mutations have been
290 described (13, 22). This apparent dichotomy may reflect environmental differences between
291 individuals or between niches within the host. Where divalent cations or other positively
292 charged molecules, including polyamines, can be co-opted to buffer membrane charge, loss
293 of function *pmrB* mutations may be retained due to the advantages they confer in terms of
294 lysozyme resistance and enhanced adherence to host surfaces (28). However, under
295 conditions where cationic molecules are scarce, activating mutations in *pmrB* would likely
296 confer a greater advantage, by promoting the LPS modifications that reduce binding of
297 antimicrobials to the bacterial outer membrane.

298

299 The differences in the kinetics of interaction with spermidine in wild type and PmrB-deficient
300 LESB65 suggest that surface charge may influence the capacity of *P. aeruginosa* to utilise
301 exogenous polyamines. Whilst it is clear that detection of divalent cations through PhoPQ
302 and PmrAB can modulate polyamine synthesis and uptake pathways, as well as inducing
303 surface charge modifications, it remains to be determined whether direct sensing of
304 polyamine abundance can modulate those same processes. An ability to alter surface

305 charge, and thus change the efficiency of polyamine binding, in response to the local
306 availability of those molecules, would offer advantages in metabolic resource management.

307

308 Similarly, whilst the findings presented here demonstrate spermidine binding to the surface
309 of *P. aeruginosa*, it is unclear whether the changes in antimicrobial susceptibility and biofilm
310 formation that we observed are a direct result of that physical interaction or whether they are
311 a consequence of polyamine-induced signalling. The increase in positive charge associated
312 with spermidine coating of the outer membrane may be sufficient to explain the increased
313 resistance to cationic antimicrobials such as colistin, and spermidine might act as a substrate
314 for biofilm formation, encourage greater surface interactions via the change in membrane
315 charge or aid in chelation of negatively charged biofilm DNA. However, we can't rule out
316 further contributions from spermidine-induced signalling and others have reported an effect
317 of exogenous polyamines on bacterial pathogen gene expression, including in *P. aeruginosa*
318 (29, 30).

319

320 The composition and charge of the outer membrane of Gram-negative bacteria are key
321 determinants of antimicrobial resistance and major barriers to antibiotic uptake (31). The
322 findings presented here go some way towards explaining the dichotomy of retention of loss-
323 of-function *pmrB* mutations in *P. aeruginosa*, in the face of antimicrobial pressure. The
324 susceptibility of PmrB-deficient LESB65 to antimicrobials *in vitro* did not translate to
325 susceptibility within the lung environment and this may be explained by buffering of the
326 negatively-charged outer membrane with host-derived cationic molecules, including
327 spermidine. This highlights the need to perform antimicrobial susceptibility testing under
328 conditions that are relevant to infection and that capture key environmental cues that are
329 sensed by pathogens or with which they interact. This is a particular challenge for those
330 interested in pathogens of the CF lung, given the complexity of that environment and the
331 difficulty in replicating its physical, chemical and microbiological features in the laboratory.

332 However, substantial progress has been made in this area (32), through use of metabolic
333 profiling of CF pathogens (33) and analytical methods that utilise next-generation sequencing
334 data to aid in the benchmarking of new models that aim to replicate conditions of the CF lung
335 (34). As models continue to be refined, consideration should be given to the inclusion of host-
336 derived factors, including polyamines, that might influence pathogen membrane charge and
337 antimicrobial susceptibility.

338

339 **Materials and methods**

340 **Bacteria and culture conditions**

341 *P. aeruginosa* Liverpool Epidemic Strain (LES)B65, LESB65 $\Delta pmrB$, PAO1 and PAO1 $\Delta pmrB$
342 were used throughout. Deletion of *pmrB* in LESB65 and PAO1 was performed as part of a
343 previous study (22). Bacterial stocks were stored at -80°C in 15% (v/v) glycerol. Prior to
344 experiments, isolates were streaked onto Mueller Hinton (MH) agar and then liquid cultures
345 were prepared in MH broth, unless otherwise stated, from a single colony, and incubated at
346 37°C in a shaking incubator (180 rpm).

347

348 **Sputum samples**

349 Sputum samples were collected from people with CF at the Adult CF centre (Liverpool Heart
350 and Chest Hospital) during periods of stable infection and periods of exacerbation in
351 accordance with ethical approval (IRAS:216408, ethics reference no: 17/NW/0091). Samples
352 were expectorated between 2017 and 2020, and stored at -80°C within 2 h of production.

353

354 **Chemicals and reagents**

355 Antibiotics and spermidine were purchased from Sigma-Aldrich (Sigma, UK). Stock solutions
356 were prepared using DEPC water and filtered through 0.22 μ m syringe filter.

357

358 **LESB65 infection of mice**

359 All infections were performed at the University of Liverpool with prior approval by the UK
360 Home Office and the University of Liverpool Ethics Committee. Female BALB/c mice of 6-8
361 weeks of age (Charles River, UK) were used for infection experiments and housed in
362 individually ventilated cages. Mice were acclimatised for one week prior to infection. Mice
363 were randomly assigned to an experimental group on arrival at the unit by staff with no role
364 in study design. For infection, 2×10^6 colony forming units of mid-exponential growth *P.*
365 *aeruginosa* were instilled into the nares of mice that had been lightly anaesthetised with a
366 mixture of isoflurane and oxygen. At 6 and 24 hours post-infection, mice were intranasally
367 administered a 50 μ l dose of 400 μ g/ml colistin in PBS or else PBS only for control animals,
368 under light anaesthesia. Following this, cage labels were reversed to blind researchers to
369 experimental groups. Mice were culled at 48 hours post-infection and upper airway (sinus
370 and nasopharynx) tissue and lungs were removed post-mortem and homogenised in 3 ml
371 PBS using an IKA T10 handheld tissue homogeniser (IKA, USA). Homogenates were serially
372 dilution onto *Pseudomonas* selective agar (Oxoid, UK) for enumeration of infectious burden.
373 Following enumeration, researchers were unblinded. No animals were excluded from
374 analysis.

375

376 **Spermidine ELISA**

377 Spermidine was quantified from lysates of overnight *P. aeruginosa* cultures, from mouse
378 upper airway (sinus and nasopharynx) and lower airway (lung) tissue homogenates, and from
379 CF sputum. Bacterial lysates were prepared by sonication. Overnight cultures were pelleted
380 by centrifugation and resuspended in 1 ml PBS prior to sonication. Mouse tissues were
381 dissected at 48 hours post intranasal administration of 2×10^6 colony forming units of mid-
382 log phase LESB65 (infected group) or PBS (control group). Competitive ELISA was
383 performed in precoated 96-well plates, according to manufacturer's instructions (Abbexa).

384

385 **Minimum inhibitory concentration assays**

386 MIC assays were performed by broth microdilution. Isolates were first streaked onto fresh
387 MH agar, and then a single colony from each plate was further grown overnight in 5 ml MH
388 broth on an orbital shaker (180 r.p.m) at 37 °C. A fresh dilution in MH broth was made by
389 incubating 200 µl of the overnight culture in 5 ml MH media. A hundred microliters of this
390 culture was incubated in 96 well-plates with 100 µl of 1:2 serially diluted antibiotic in MH broth.

391 After a 24 h static incubation at 37 °C, the OD₆₀₀ was determined to assess bacterial growth.

392

393 **MIC assays with spermidine**


394 MIC assays were performed as above, with the addition of 4 mM spermidine to the assay
395 throughout or using *P. aeruginosa* that had been pre-incubated with 4 mM spermidine. In the
396 latter case, overnight cultures of *P. aeruginosa*, prepared as above, were pelleted by
397 centrifugation and resuspended in 5 ml PBS containing 4mM spermidine. Tubes were
398 incubated at 37 °C, 180 r.p.m. for 30 minutes and then bacteria were again pelleted and
399 resuspended in MH broth for use in MIC assays.

400

401 **Synthesis of fluorescent spermidine-NBD (nitrobenzoxadiazole)**

402 7-Nitro-2,1,3-benzoxadiazol-4-N⁸-spermidine hydrogen chloride

403 (NBD-N⁸-Spermidine)



405 A solution of N¹-N⁴-Bis-Boc-spermidine (50 mg, 0.29 mmol) in acetonitrile (2.0 ml) was added
406 to 4-chloro-7-nitrobenzofuran (58 mg, 0.29 mmol) and caesium carbonate (94 mg, 0.29
407 mmol) and heated to 80 °C under reflux conditions for 40 minutes. The reaction mixture was
408 concentrated *in vacuo*, and purified through a silica plug, flushed with EtOAc to elute the boc

409 protected fluorophore. The compound was then dissolved in a solution of 4M HCl in dioxane
410 (5 mL) and stirred for 3 hours at room temperature, before removing the solvent *in vacuo*.
411 The crude mixture was dissolved in DCM was and extracted with water. The aqueous layer
412 was lyophilised to give NBD-N⁸-Spermidine as a hydrochloride salt (35) as a red, amorphous
413 solid and a global yield of 74%, after both the addition of the fluorophore and the subsequent
414 removal of the boc protection group. δ_{H} (500 MHz, D₂O) 8.48 (1H, d, J 9.0, Ar 6-H), 6.35 (1H,
415 d, J 9.0, Ar 5-H), 3.66 (2H, broad s, 2-H2), 3.17 (4H, m, 5- and 7-H2), 3.11 (2H, appt t, J 7.9,
416 9-H2), 2.08 (2H, apt tt, J 8, 2.4, 8-H2), 1.88 (4H, m, 3 and 4-H2). δ_{C} (125 MHz, D₂O) 147.2
417 (Ar 4-C), 145.0 (Ar 7a-C), 144.7 (Ar 3a-C), 139.8 (Ar 5-C), 100.6 (Ar 6-C), 48.0 (5-C), 45.1
418 (7-C), 43.6 (2-C), 37.2 (9-C), 25.3 (3-C), 24.4 (8-C), 23.8 (4-C). HRMS (ESI): C₁₃H₂₀N₆O₃
419 requires [M+H]⁺, calculated 309.1675 , found 309.1673.

420

421 **Flow cytometry analysis of spermidine-*P. aeruginosa* interactions**

422 *P. aeruginosa* were pre-incubated with 4 mM spermidine-NBD or unlabelled spermidine,
423 following the same protocol as that used for MIC assays. Following incubation, bacteria were
424 pelleted by centrifugation and resuspended in PBS. Immediately, and at 30, 60, 120, 180 and
425 240 minutes, 200 μ l samples were removed from the cultures and analysed for NBD
426 fluorescence on a FACS Aria II flow cytometer (BD Biosciences). Twenty thousand individual
427 bacteria were recorded. Side-scatter and forward-scatter limits for bacterial flow cytometry
428 were pre-determined using *P. aeruginosa* stained with the DNA dye thiazole orange (Sigma
429 Aldrich).

430

431 **Biofilm assay**

432 Biofilm experiments were set up using overnight cultures. Each culture was first diluted 1:100
433 in fresh broth, then added to 96 well plates and incubated for 48 hours at 37° C under static
434 conditions. Plates were washed twice with PBS and stained with 200 μ L of a 0.25% solution
435 of crystal violet in water. After incubating at room temperature for 15 minutes, the plates were

436 rinsed twice with water and allowed to dry for 24 hours. The stain was then dissolved in 1 mL
437 of 25% acetic acid in water and incubated at room temperature for 2 minutes. Biofilm
438 formation was quantified by measuring the optical density of this final solution at 590 nm.

439

440 **Statistics**

441 Data analysis was carried out using GraphPad Prism v.8.02 and JMP version 14.0. Data were
442 tested for normality. One-way or two-way ANOVA was used for comparison between groups,
443 and post-hoc analysis included correction for multiple comparisons. Significance was
444 determined from label free proteomics data using Progenesis QI.

445

446 **Study Approval**

447 Ethical approval for collection of CF sputum was obtained from the North West Research
448 Ethics Committee (IRAS:216408, ethics reference no: 17/NW/0091). Written informed
449 consent was obtained from all study participants, prior to enrolment. Ethical approval for
450 animal studies was obtained from the UK Home Office (project licence PP2072053) and the
451 University of Liverpool Animal Welfare Ethical Review Board.

452

453 **Author Contributions**

454 CW, AK, MW, DN and JF designed the study, contributed resources and reagents and
455 supervised staff. CH, AG, AC, TJ, DN performed experiments. CH, AG, AC, MW, DN, JF
456 analysed data. CH, DN, JF wrote the manuscript, with input from all authors.

457

458 **Acknowledgements**

459 This work was funded by an Action Medical Research grant awarded to JF, DN, CW and AK
460 (Grant number GN2444). AC was supported by an MRC Doctoral Training Partnership
461 studentship. AG and DN were supported by a Wellcome and Royal Society Sir Henry Dale

462 Fellowship awarded to DN (Grant Number 204457/Z/16/Z). JF was supported by a Medical
463 Research Foundation Fellowship (Grant number MRF-091-0006-RG-FOTHE). JW was
464 supported by a Leverhulme Trust Research Grant (Grant number RPG-2018-030).

465

466 **References**

- 467 1. Rajan S, and Saiman L. Pulmonary infections in patients with cystic fibrosis. *Semin
468 Respir Infect.* 2002;17(1):47-56.
- 469 2. Sadikot RT, Blackwell TS, Christman JW, and Prince AS. Pathogen-host interactions
470 in *Pseudomonas aeruginosa* pneumonia. *Am J Respir Crit Care Med.*
471 2005;171(11):1209-23.
- 472 3. Lyczak JB, Cannon CL, and Pier GB. Lung infections associated with cystic fibrosis.
473 *Clin Microbiol Rev.* 2002;15(2):194-222.
- 474 4. Langendijk RF, Neill DR, and Fothergill JL. The Building Blocks of Antimicrobial
475 Resistance in *Pseudomonas aeruginosa*: Implications for Current Resistance-
476 Breaking Therapies. *Front Cell Infect Microbiol.* 2021;11:665759.
- 477 5. Govan JR, and Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid
478 *Pseudomonas aeruginosa* and *Burkholderia cepacia*. *Microbiol Rev.* 1996;60(3):539-
479 74.
- 480 6. Johnson L, Mulcahy H, Kanevets U, Shi Y, and Lewenza S. Surface-localized
481 spermidine protects the *Pseudomonas aeruginosa* outer membrane from antibiotic
482 treatment and oxidative stress. *J Bacteriol.* 2012;194(4):813-26.
- 483 7. Gunn JS. Bacterial modification of LPS and resistance to antimicrobial peptides. *J
484 Endotoxin Res.* 2001;7(1):57-62.
- 485 8. Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, et al.
486 Unique lipid a modifications in *Pseudomonas aeruginosa* isolated from the airways of
487 patients with cystic fibrosis. *J Infect Dis.* 2007;196(7):1088-92.
- 488 9. Raetz CR, Reynolds CM, Trent MS, and Bishop RE. Lipid A modification systems in
489 gram-negative bacteria. *Annu Rev Biochem.* 2007;76:295-329.
- 490 10. McPhee JB, Lewenza S, and Hancock RE. Cationic antimicrobial peptides activate a
491 two-component regulatory system, PmrA-PmrB, that regulates resistance to
492 polymyxin B and cationic antimicrobial peptides in *Pseudomonas aeruginosa*. *Mol
493 Microbiol.* 2003;50(1):205-17.
- 494 11. McPhee JB, Bains M, Winsor G, Lewenza S, Kwasnicka A, Brazas MD, et al.
495 Contribution of the PhoP-PhoQ and PmrA-PmrB two-component regulatory systems
496 to Mg²⁺-induced gene regulation in *Pseudomonas aeruginosa*. *J Bacteriol.*
497 2006;188(11):3995-4006.
- 498 12. Mulcahy H, Charron-Mazenod L, and Lewenza S. Extracellular DNA chelates cations
499 and induces antibiotic resistance in *Pseudomonas aeruginosa* biofilms. *PLoS
500 Pathog.* 2008;4(11):e1000213.
- 501 13. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, et al.
502 PmrB mutations promote polymyxin resistance of *Pseudomonas aeruginosa* isolated
503 from colistin-treated cystic fibrosis patients. *Antimicrob Agents Chemother.*
504 2012;56(2):1019-30.
- 505 14. Moskowitz SM, Ernst RK, and Miller SI. PmrAB, a two-component regulatory system
506 of *Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial
507 peptides and addition of aminoarabinose to lipid A. *J Bacteriol.* 2004;186(2):575-9.

508 15. Han ML, Zhu Y, Creek DJ, Lin YW, Anderson D, Shen HH, et al. Alterations of
509 Metabolic and Lipid Profiles in Polymyxin-Resistant *Pseudomonas aeruginosa*.
510 *Antimicrob Agents Chemother*. 2018;62(6).

511 16. Winsor GL, Griffiths EJ, Lo R, Dhillon BK, Shay JA, and Brinkman FS. Enhanced
512 annotations and features for comparing thousands of *Pseudomonas* genomes in the
513 *Pseudomonas* genome database. *Nucleic Acids Res*. 2016;44(D1):D646-53.

514 17. Shah P, and Swiatlo E. A multifaceted role for polyamines in bacterial pathogens.
515 *Mol Microbiol*. 2008;68(1):4-16.

516 18. Kwon DH, and Lu CD. Polyamine effects on antibiotic susceptibility in bacteria.
517 *Antimicrob Agents Chemother*. 2007;51(6):2070-7.

518 19. Grasemann H, Shehnaz D, Enomoto M, Leadley M, Belik J, and Ratjen F. L-
519 ornithine derived polyamines in cystic fibrosis airways. *PLoS One*.
520 2012;7(10):e46618.

521 20. Twomey KB, Alston M, An SQ, O'Connell OJ, McCarthy Y, Swarbreck D, et al.
522 Microbiota and metabolite profiling reveal specific alterations in bacterial community
523 structure and environment in the cystic fibrosis airway during exacerbation. *PLoS*
524 *One*. 2013;8(12):e82432.

525 21. Fothergill JL, Neill DR, Loman N, Winstanley C, and Kadioglu A. *Pseudomonas*
526 *aeruginosa* adaptation in the nasopharyngeal reservoir leads to migration and
527 persistence in the lungs. *Nat Commun*. 2014;5:4780.

528 22. Bricio-Moreno L, Sheridan V, Goodhead IB, Armstrong S, Wong JKL, Waters EM, et
529 al. Evolutionary trade-offs associated with loss of PmrB function in host-adapted
530 *Pseudomonas aeruginosa*. *Nat Commun*. 2018.

531 23. Bolard A, Schniederjans M, Haussler S, Tripionney P, Valot B, Plesiat P, et al.
532 Production of Norspermidine Contributes to Aminoglycoside Resistance in pmrAB
533 Mutants of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2019;63(10).

534 24. Karatan E, and Michael AJ. A wider role for polyamines in biofilm formation.
535 *Biotechnol Lett*. 2013;35(11):1715-7.

536 25. McGinnis MW, Parker ZM, Walter NE, Rutkovsky AC, Cartaya-Marin C, and Karatan
537 E. Spermidine regulates *Vibrio cholerae* biofilm formation via transport and signaling
538 pathways. *FEMS Microbiol Lett*. 2009;299(2):166-74.

539 26. Goytia M, Dhulipala VL, and Shafer WM. Spermine impairs biofilm formation by
540 *Neisseria gonorrhoeae*. *FEMS Microbiol Lett*. 2013;343(1):64-9.

541 27. Moore MP, Lamont IL, Williams D, Paterson S, Kukavica-Ibrulj I, Tucker NP, et al.
542 Transmission, adaptation and geographical spread of the *Pseudomonas aeruginosa*
543 Liverpool epidemic strain. *Microb Genom*. 2021;7(3).

544 28. Bricio-Moreno L, Sheridan VH, Goodhead I, Armstrong S, Wong JKL, Waters EM, et
545 al. Evolutionary trade-offs associated with loss of PmrB function in host-adapted
546 *Pseudomonas aeruginosa*. *Nat Commun*. 2018;9(1):2635.

547 29. Durand JM, and Bjork GR. Putrescine or a combination of methionine and arginine
548 restores virulence gene expression in a tRNA modification-deficient mutant of
549 *Shigella flexneri*: a possible role in adaptation of virulence. *Mol Microbiol*.
550 2003;47(2):519-27.

551 30. Zhou L, Wang J, and Zhang LH. Modulation of bacterial Type III secretion system by
552 a spermidine transporter dependent signaling pathway. *PLoS One*.
553 2007;2(12):e1291.

554 31. Delcour AH. Outer membrane permeability and antibiotic resistance. *Biochim*
555 *Biophys Acta*. 2009;1794(5):808-16.

556 32. Bonfield TL. Preclinical Modeling for Therapeutic Development in Cystic Fibrosis. *Am*
557 *J Respir Crit Care Med*. 2020;201(3):267-8.

558 33. Moyne O, Castelli F, Bicout DJ, Boccard J, Camara B, Cournoyer B, et al.
559 Metabotypes of *Pseudomonas aeruginosa* Correlate with Antibiotic Resistance,

560 Virulence and Clinical Outcome in Cystic Fibrosis Chronic Infections. *Metabolites*.
561 2021;11(2).

562 34. Cornforth DM, Diggle FL, Melvin JA, Bomberger JM, and Whiteley M. Quantitative
563 Framework for Model Evaluation in Microbiology Research Using *Pseudomonas*
564 *aeruginosa* and Cystic Fibrosis Infection as a Test Case. *mBio*. 2020;11(1).

565 35. Jagu E, Pomel S, Pethe S, Cintrat JC, Loiseau PM, and Labruere R. Spermine-NBD
566 as fluorescent probe for studies of the polyamine transport system in *Leishmania*
567 *donovani*. *Bioorg Med Chem Lett*. 2019;29(14):1710-3.

568